UroGen Pharma (URGN) Profit After Tax Growth (5y) (2022 - 2026)

UroGen Pharma (URGN) Profit After Tax Growth (5y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 UroGen Pharma 2.36 Bn 2.25 Bn 65.88 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 11.41%
Mar 31, 2026 1.98%
Dec 31, 2025 2.89%
Sep 30, 2025 -2.77%
Jun 30, 2025 -9.76%
Mar 31, 2025 -3.03%
Dec 31, 2024 0.76%
Sep 30, 2024 -1.25%
Jun 30, 2024 -8.25%
Mar 31, 2024 -8.56%
Dec 31, 2023 -1.87%
Sep 30, 2023 -1.28%
Jun 30, 2023 -6.01%
Mar 31, 2023 -17.69%
Dec 31, 2022 -23.37%
Sep 30, 2022 -144.30%
Jun 30, 2022 -33.91%
Mar 31, 2022 -52.77%